Johnson & Johnson (JNJ, Financial) is pushing forward with significant developments across its Innovative Medicine and MedTech sectors. The company's escalating pipeline of therapies aims to address a wide range of medical conditions.
In the realm of innovative treatments, the company is progressing with nipocalimab for generalized myasthenia gravis (gMG), a condition characterized by muscle weakness. Additionally, it is advancing the subcutaneous formulation of RYBREVANT for treating non-small cell lung cancer (NSCLC), enhancing its administration options. TREMFYA is also being developed in a subcutaneous form to target ulcerative colitis (UC), offering new hope for patients.
Furthermore, the TAR-200 device is being evaluated for its effectiveness in non-muscle invasive bladder cancer (NMIBC), while icotrokinra is under study for both psoriasis (PsO) and UC. The RYBREVANT therapy is being expanded into head and neck cancer (HNC) treatments, and CAPLYTA is now being looked at for adjunctive treatment in major depressive disorder (aMDD).
On the MedTech front, Johnson & Johnson is making strides with its OTTAVA project, showing substantial progress. The company is also advancing various technologies in cardiovascular care, indicating a commitment to tackling heart-related conditions with innovative solutions.
These developments underline Johnson & Johnson's dedication to enhancing patient care through a robust pipeline of treatments and technologies aimed at addressing critical medical needs.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for Johnson & Johnson (JNJ, Financial) is $170.47 with a high estimate of $185.00 and a low estimate of $150.00. The average target implies an upside of 10.44% from the current price of $154.36. More detailed estimate data can be found on the Johnson & Johnson (JNJ) Forecast page.
Based on the consensus recommendation from 26 brokerage firms, Johnson & Johnson's (JNJ, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Johnson & Johnson (JNJ, Financial) in one year is $187.89, suggesting a upside of 21.72% from the current price of $154.36. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Johnson & Johnson (JNJ) Summary page.
